PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31740864-0	2019	Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.	erlotinib	46-55	epidermal growth factor receptor	Homo sapiens	107-139	
31740864-0	2019	Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.	erlotinib	80-89	epidermal growth factor receptor	Homo sapiens	107-139	
31740864-1	2019	Objective: To assess the efficacy and tolerability of erlotinib in combination with radiation therapy followed by maintenance therapy in Stage III and IV, epidermal growth factor receptor mutationpositive adenocarcinoma lung patients.	erlotinib	54-63	epidermal growth factor receptor	Homo sapiens	155-187	
31740864-14	2019	CONCLUSIONS: Concurrent radiotherapy with erlotinib was effective and well-tolerated in patients with locally advanced adenocarcinoma lung harbouring epidermal growth factor receptor mutation.	erlotinib	42-51	epidermal growth factor receptor	Homo sapiens	150-182